乳房切除术后放疗与腋窝手术范围对1-2枚阳性淋巴结乳腺癌患者的疗效评估
基于美国国家癌症数据库2012至2021年71,776例pT1-T2期乳房切除术后1-2枚阳性淋巴结乳腺癌患者,55%接受乳房切除术后放疗。倾向加权Cox模型显示放疗与死亡风险降低26%相关(HR 0.74,95%CI 0.70-0.78),加做腋窝淋巴结清扫未显示总生存获益(OR 0.98,95%CI 0.92-1.03)。
要点
- 早期乳腺癌1-2枚阳性淋巴结乳房切除术后,放疗与总生存改善相关。
- 加做腋窝淋巴结清扫未带来额外总生存获益。
- 接受放疗者更多为T2期、2枚阳性淋巴结且行前哨淋巴结活检。
核心结论
- 国家癌症数据库数据支持早期乳腺癌1-2枚阳性淋巴结患者在乳房切除术后放疗时省略进一步腋窝手术。
- 数据证实了多数前瞻性研究显示的乳房切除术后放疗获益。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2012至2021年pT1-T2期乳房切除术后1-2枚阳性淋巴结的女性乳腺癌患者。
- 共71,776例患者符合纳入标准,其中39,319例(55%)接受乳房切除术后放疗。
- 采用倾向加权Kaplan-Meier生存分析和Cox比例风险模型比较组间总生存。
主要发现
- 接受放疗者更年轻、合并症更少,更可能有T2期病变(51%)、2枚阳性淋巴结(33% vs 19%,P < .001)和接受前哨淋巴结活检(49% vs 40%,P < .001)。
- 加做腋窝淋巴结清扫未显示总生存获益。
- 倾向加权Cox模型显示放疗与死亡风险降低26%相关(HR 0.74,95%CI 0.70-0.78),加做腋窝淋巴结清扫无获益(OR 0.98,95%CI 0.92-1.03)。
关键数值与推荐
- 多数患者为T1c期(36%)或T2期(51%),75%有1枚阳性淋巴结。
- 56%的患者接受了腋窝淋巴结清扫。
- 放疗与死亡风险降低26%相关(HR 0.74,95%CI 0.70-0.78)。
- 加做腋窝淋巴结清扫的OR为0.98(95%CI 0.92-1.03)。
临床怎么用
- 对于pT1-T2期乳房切除术后1-2枚阳性淋巴结的乳腺癌患者,可考虑给予乳房切除术后放疗。
- 在此类接受放疗的患者中,可考虑省略进一步腋窝淋巴结清扫。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation therapy prevents locoregional recurrence and improves outcomes in patients with positive lymph nodes undergoing mastectomy. Axillary lymph node dissection combined with radiation has not provided additional survival benefit. We evaluated the efficacy of postmastectomy radiation therapy and the effect of extent of axillary surgery. METHODS: Women with pT1-T2 breast cancer undergoing mastectomy with 1-2 positive lymph nodes were identified within the National Cancer Database from 2012 to 2021. Propensity-weighted Kaplan-Meier survival and Cox proportional hazards models were constructed to compare overall survival between groups. RESULTS: A total of 71,776 patients met inclusion criteria, with 39,319 (55%) receiving postmastectomy radiation therapy. Most patients had T1c (36%) or T2 (51%) disease and 1 positive lymph node (75%). A little over half (56%) underwent axillary lymph node dissection. Patients receiving postmastectomy radiation therapy were younger; had fewer comorbidities; and were more likely to have T2 disease, have 2 positive lymph nodes (33% vs 19%, P < .001), and undergo sentinel lymph node biopsy (49% vs 40%, P < .001). Ten-year OS probabilities were higher for patients receiving postmastectomy radiation therapy compared with patients who did not. Adding axillary lymph node dissection did not show an overall survival benefit. These differences persisted in a propensity-weighted Cox model adjusting for significant prognostic factors, where postmastectomy radiation therapy was associated with a 26% reduction in risk of death (hazard ratio 0.74 [95% confidence interval 0.70-0.78]), but the addition of axillary lymph node dissection was not (odds ratio 0.98 [0.92-1.03]) CONCLUSION: Data from the National Cancer Database support omission of further axillary surgery in patients with early-stage breast cancer with 1 to 2 positive lymph nodes undergoing postmastectomy radiation therapy and confirm the benefit of postmastectomy radiation therapy shown in most prospective studies.
引用
- Donica WRF, Gaskins J, Egger ME, et al. Evaluating the effect of postmastectomy radiotherapy and extent of axillary surgery in cancer patients with 1-2 positive lymph nodes. Surgery. 2026. PMID: 42001644. doi:10.1016/j.surg.2026.110204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。